The Government of Canada has announced its intention to merge BDC and EDC. Today, BDC remains BDC, and we remain fully committed to Canadian entrepreneurs. To learn more, click here.

The Government of Canada has announced its intention to merge BDC and EDC. Today, BDC remains BDC, and we remain fully committed to Canadian entrepreneurs. To learn more, click here.
FR
Search
Search
Conjuchem logo
Exited company

Conjuchem

Details
Region
Quebec
Industry sector
Medical/health
Investment year
1998
Fund
Healthcare Venture Fund
Learn more
About the company

ConjuChem creates novel, next-generation medicines using unique, long-acting therapeutic peptides. Underlying all ConjuChem compounds are bioconjugation platforms called Drug Affinity Complex (DACTM) and Preformed Conjugate-Drug Affinity Complex (PC-DACTM). When applied to a given peptide, DACTM and PC-DACTM can create new drugs with similar therapeutic activities but with significantly longer durations of activity and improved safety profiles.